Transitioning Treatment in Diabetic Retinopathy

Posttest

You passed! Review the answers below.

Please try again. The questions you answered incorrectly are highlighted in red below.

Question 1
Which of the following was seen in the phase 3 PANORAMA study that compared intravitreal aflibercept with sham in the treatment of patients with diabetic retinopathy (DR)?
Please complete this question.
Please try again.

Correct Answer: C

Rationale: Patients treated with intravitreal aflibercept had significantly greater rates of ≥2-step improvement in DR severity score at 24 and 52 weeks. Intravitreal aflibercept–treated patients had significantly lower rates of vision-threatening complications compared with sham. Patients treated with aflibercept received treatment every 8 or 16 weeks.

Question 2
Which of the following was seen in the DRCR.net Protocol S study, which compared panretinal photocoagulation (PRP) versus ranibizumab for proliferative diabetic retinopathy?
Please complete this question.
Please try again.

Correct Answer: B

Rationale: Patients treated with ranibizumab had superior mean BCVA after 2 years compared with those treated with PRP. Decreased rates of vitrectomy and risk of developing CI-DME were noted.

Back